234 words 9 Main text: 4173 words 10 2 ABSTRACT 11 Most current diagnostic tests for transmissible spongiform encephalopathies (TSE) rely on the 12 presence of PK-resistant PrP Sc (PrP-res) in post-mortem tissues as indicative of TSE disease.
INTRODUCTION
ARR/ARR and VRQ/ARR do not show any PrP-res accumulation in the spleen (4). In terminal 48 BSE-infected cattle no PrP-res has been detected in the spleen tissue (5, 6) , indicating that the 49 LRS is not involved in the disease pathogenesis of BSE in cattle. However, in sheep 50 experimentally infected with BSE, TSE infectivity and PrP Sc has been identified in the peripheral 51 4 tissues including the LRS and the spleen (7, 8) . In murine models, infectivity levels in the spleen 52 tissue have been shown to have an initial increase in titre within days of inoculation that then 53 plateaus for the remainder of the disease duration, long before infectivity is detected in the CNS 54 (9, 10) . At disease end-point, the spleen contains lower titres of infectivity than the 55 corresponding brain tissue, regardless of the route of infection. For example, it has been shown 56 that wild-type/139A mouse spleens contain 2-3log 10 units less infectivity than the brain (11). In 57 correlation with the infectivity data, the levels of PrP-res in the spleen of 139A infected mice 58 were 500-fold less than those observed in the brain tissue at terminal stage of disease (11) . 59 Further studies identified that the level of PrP-res was 200-300 fold less in the spleen than in the 60 brain of mice infected with a mouse-adapted strain of Gerstmann-Sträussler-Scheinker (GSS) 61 originating from Fukuoka-1 GSS case (12) . 62 If peripheral levels of infectivity are equally low in all cases of TSE disease, the current safety 63 measures in place for removal of specified risk material should prevent any infected material 64 from entering the food chain for human consumption. However, a number of natural and 65 experimental TSE isolates have been identified that do not have the expected association 66 between levels of TSE infectivity and PrP-res in all tissues (2, 3, (13) (14) (15) . Indeed one study of 67 atypical scrapie in sheep identified the presence of high levels of TSE infectivity in the spleen 68 tissue, despite the absence of abnormal PrP (13) . Given that the majority of current diagnostic 69 tests rely on the presence of PrP-res as indicative of TSE disease, disease cases and tissues where 70 PrP-res is absent may be falsely identified as negative. Further, the disparity between PrP-res and 71 TSE infectivity levels may result in an underestimation of infectivity levels that are present in 72 peripheral tissues that are allowed to enter the food chain, increasing the potential for zoonotic 73 transfer.
5
We have previously identified a unique mouse model of infectious TSE disease that highlights 75 the discrepancy between PrP-res levels and corresponding TSE infectious titres (14, 16, 17) .
76
Previous work has performed extensive characterisation of the relationship between PrP-res and 77 TSE infectivity in the brain tissue of these disease models. Here we investigate the relationship 78 between PrP-res and TSE infectivity within the peripheral spleen tissue of these mice using both 79 biochemical analyses and mouse bioassay, and demonstrate that extremely high levels of 80 infectivity can be present in peripheral tissue without a corresponding increase in PrP-res. If 81 peripheral tissues can be as infectious as brain tissue this could represent an increased risk to 82 food safety. Indeed if the correct combination of host species, PrP genotype and strain of agent 83 was to occur naturally that resulted in high peripheral infectivity, infected peripheral tissue could 84 have the potential to enter the food chain. Office Regulations (Animals (Scientific Procedures) Act of 1986). Brain and spleen tissue was 106 7 recovered at post-mortem for biochemical and immunohistochemical analysis. Half-brain 107 sections (6µm) were stained using haematoxylin and eosin and the abundance of TSE-related 108 vacuolation was assessed at nine grey-matter regions (medulla, cerebellum, superior colliculus, 109 hypothalamus, thalamus, hippocampus, septum, retrospinal cortex, cingulated and motor cortex) 110 and three regions of white matter (cerebellar white matter, midbrain white matter and cerebral 111 peduncle) as described previously (10). DNA was extraction from tail tissue that was taken post 112 mortem. PCR and restriction enzyme digestion was performed as previously described (16) to 113 confirm the presence of the P101L mutation.
114

Sub-passage inoculations 115
Inocula were prepared from the brains and spleens of two 101LL/GSS mice (designated 116 101LL/GSS(a) and 101LL/GSS(b)) and two 101LL/263K mice (designated 101LL/263K(c) and 117 101LL/263K(d)) that all had confirmed clinical TSE disease with associated TSE-vacuolar 118 pathology. Inoculum was prepared from a wild-type/79A mouse brain and spleen tissue as 119 controls (designated wild-type/79A(e)). A 10% (w/v) homogenate of each tissue was prepared in 120 sterile saline and was used to produce a dilution series of 10 -2 , 10 -3 and 10 -4 for each 121 homogenate. Utilising previous data (14) it was hypothesised that a 10 -4 dilution of brain 122 homogenate would produce a 100% attack rate. Given the expected 2-3log 10 difference in TSE 123 infectivity titres between brain and spleen tissues in murine models (11), the inoculation of these 124 three dilutions was predicted to allow the identification of difference in incubation period 125 between tissues, and provide an estimation in difference in titre. Each dilution (20µl) was 126 inoculated intra-cerebrally under anaesthesia into groups of 101LL mice for 101LL/GSS and 127 101LL/263K inocula and wild-type 129/Ola mice for wild-type/79A inocula. Dilutions of brain 128 homogenate were inoculated into groups of 6 mice at 10 -2 and 10 -3 dilutions and 8 mice at 10 -4 129 8 dilution. Dilutions of spleen homogenate were inoculated into groups of 6 mice at 10 -2 dilution 130 and 8 mice at 10 -3 and 10 -4 dilution due to the predicted lower titres.
131
Immunohistochemistry to detect PrP deposition 132 Immunohistochemistry was performed to detect PrP deposition in the brain tissue. Briefly, 133 following fixation in 10% formal saline, brains were treated for 1.5 hours in 98% formic acid, 134 dissected and embedded in paraffin. Sections (6µm) of brain tissue were hydrated, autoclaved for 135 15 minutes at 121˚C and incubated in 98% formic acid for 5 minutes to expose the PrP epitopes.
136
Sections were incubated in 1% hydrogen peroxide/methanol and washed in 0.2% BSA/PBS.
137
Sections were blocked with normal goat serum, incubated overnight in anti-PrP monoclonal 138 antibody 6H4 (Prionics), (0.5µg/ml) and then with secondary anti-mouse biotinylated antibody 139 (Jacksons Immuno Research Laboratories) (2µg/ml) for 1 hour. Sections were processed using 140 the ABC Elite kit (Vector Laboratories) and the signal was visualised by a reaction with 141 hydrogen perozidize-activated diaminobenzidine.
142
Precipitation of PrP-res with NaPTA from primary spleen tissue 143 Sodium phosphotungstic acid (NaPTA) precipitation has previously been shown to increase the 144 sensitivity of immunoblotting for the detection of PrP Sc (19). All incubations were performed at 145 37˚C with agitation. Briefly, spleen tissue from terminal animals was homogenised in 0.1M Tris-146 HCl (pH7.4) to a 10% (w/v) homogenate with a glass dounce homogeniser. Cellular debris was 147 removed through centrifugation at 1000 rpm for 5 minutes. An equal volume of 2% 148 Sarkosyl/0.1M Tris-HCl was added to the supernatant and incubated for 10 minutes.
149
Homogenates were digested with 50µg/ml PK for 1 hour. Digestion was stopped by the addition 150 of phenylmethylsulfonyl fluoride to 2mM. PrP-res was selectively precipitated with 0.3% (w/v) 151 NaPTA for 20 minutes. Homogenates were centrifuged 15,400g for 30 minutes. Pellets were 152 washed with 83mM EDTA, 0.1% Sarkosyl/0.1M Tris-HCl and a further 30 minutes 153 centrifugation (15,400g) produced the PrP-res pellet that was re-suspended in the appropriate 154 volume of tris-glycine sample buffer (Invitrogen) according to the starting weight of the tissue.
155
Precipitation of PrP-res with NaPTA from residual inocula and brain tissue of recipient mice 156 All incubations were performed at 37˚C with agitation to allow precipitation of PrP-res from 157 residual inocula. Briefly, to a 50µl aliquot of each 10% (w/v) homogenate, 0.1M magnesium 158 chloride was added and incubated for 15 minutes. An equal volume of 4% Sarkosyl/0.1M Tris-
159
HCl was added to the supernatant and incubated for 5 minutes. Homogenates were digested with 160 50µg/ml PK for 1 hour and precipitation of PrP-res with NaPTA performed as described for 161 spleen tissues. The PrP-res pellet was re-suspended in 15µl tris-glycine sample buffer 162 (Invitrogen) according to the starting weight of the tissue.
163
Immunoblotting of PrP-res 164
PrP-res pellets produced from NaPTA precipitation were diluted as described in the text.
165
Samples were loaded on 12% tris/glycine polyacrylamide gels (Invitrogen) and separated by 
RESULTS
171
Low levels of PrP-res in the spleen tissue of 101LL/GSS and 101LL/263K mice. 172 Spleens were harvested at cull from several 101LL transgenic mice that had been inoculated with 173 P102L GSS or hamster 263K scrapie. All spleens selected for analysis were from mice which 174 showed clinical signs of TSE disease and confirmed vacuolar pathology, but had low levels of 175 PrP deposition by immunohistochemical analysis in the brain tissue. The levels of PrP-res in the 176 spleens of infected mice were investigated to determine if PrP conversion and therefore 177 replication of infectivity was occurring in the spleen tissue of these unique disease models. It has 178 previously been shown that it is necessary to concentrate the spleen material in order to detect 179 disease-associated forms of PrP (20) and to minimise IgG cross-reactivity during the immunoblot 180 procedure. Therefore in these studies, PrP-res in spleen tissue was precipitated using sodium 181 phosphotungstic acid (NaPTA) (21) to concentrate the PrP-res present for detection by 182 immunoblotting. Analysis of the PK digested, NaPTA precipitated material identified a variation 183 in the level of PrP-res between individual spleens ( Figure 1A) . However, the level of PrP-res in 184 some 101LL/GSS and 101LL/263K spleens appeared to be lower than the level of PrP-res in the 185 wild-type/ME7 spleens from which PrP-res was isolated as a control ( Figure 1A) . In order to 186 confirm the difference in levels, doubling dilutions of the PK digested, NaPTA precipitated 187 material from 101LL/GSS and 101LL/263K and a wild-type/ME7 spleen were analysed to 188 determine the minimum tissue equivalent at which PrP-res could be detected with a semi-189 quantitative immunoblot ( Figure 1B ). 101LL/GSS spleens were shown to contain PrP-res at a 190 level similar to the PrP-res levels in a wild-type/ME7 spleen albeit with a lighter band intensity. 197 In order to confirm the presence of infectivity in spleen tissue and compare the levels of 198 infectivity present in brain and spleen from the same mouse, 10% (w/v) homogenates of a brain 199 and spleen from two 101LL/GSS and two 101LL/263K mice were prepared and used to produce 200 a dilution series (10 -2 , 10 -3 and 10 -4 ) for inoculation. 101LL/GSS and 101LL/263K brain and 201 spleen homogenates were inoculated into groups of 101LL transgenic mice. As both P102L GSS 202 and hamster 263K scrapie had been shown previously to be poorly transmissible to wild type 203 mice (16, 17), brain and spleen homogenates from murine 79A scrapie were inoculated as 204 controls. Average incubation periods to disease were similar for each brain and spleen inocula test) were observed between the average incubation periods to disease at each dilution for 207 101LL/263K. Although no statistical differences between incubation periods were observed for 208 the majority of dilutions of 101LL/GSS, the two exceptions were 101LL/GSS(a) 10 -3 dilution of 209 brain homogenate that had a significantly (p-value 8.3x10 -5 ) shorter incubation period to disease 210 than the spleen homogenate at the same dilution, and 101LL/GSS(b) 10 -2 dilution that had a 211 significantly (p-value 5.6x10 -4 ) shorter incubation period to disease from the brain homogenate 212 than the spleen homogenate. However, these significant differences were not consistent and were 213 not observed for all dilutions of the same inoculum. Overall the data (Figure 2) show that the 214 brain and spleen incubation periods were similar in 101LL/GSS and 101LL/263K tissues. In 215 comparison, significantly different incubation periods to disease were observed between brain 216 and spleen homogenates from wild-type/79A mice at each dilution. The average incubation 217 period to disease for the wild-type/79A spleen homogenates was 30-40 days longer than the 218 average incubation period to disease with the corresponding brain homogenates.
219
Analysis of PrP-res levels in residual inocula 220 Given the similar infectivity levels between the brain and spleen homogenate, we analysed the Given the different levels of PrP deposition observed by immunohistochemistry depending on 250 tissue source for 101LL/GSS, recipient brain tissue from animals receiving brain and spleen 251 inocula was analysed through PK digestion, NaPTA precipitation and immunoblotting. The 252 results ( Figure 6 ) confirm that 101LL/GSS mice that received brain homogenate had a greater 253 level of PrP-res than mice that received spleen homogenate. The differences in the levels of PrP-254 res in 101LL/GSS were shown to be present in each dilution group inoculated. In contrast, the 255 levels of PrP-res in 101LL/263K tissues were variable independent of tissue-type inoculated 256 whilst the levels of PrP-res in wild-type/79A mice were similar irrespective of the tissue type 257 inoculated. These results were confirmed through a number of different techniques including 258 standard PK digestion (performed at 37˚C without the use of NaPTA) and isolation of scrapie-259 associated fibrils (data not shown). which PrP-res was not detectable (2, 3, 13, 14) . The involvement of the lymphoreticular system 266 in TSE diseases is dependent upon the combination of host species, genotype and TSE agent. In 267 the majority of murine TSE disease models, the levels of PrP-res present in the spleen are lower 268 than those present in the brain tissue (11, 12) . However, in the disease models investigated here, 269 we have shown equally short incubation periods following sub-passage of either brain or spleen 270 homogenate from the same mouse, indicating the presence of similar levels of infectivity in both 271 tissues. This was in contrast to the wild-type 79A control which showed consistently extended 272 incubation times with spleen homogenate (30-40 days) compared to brain homogenate. Based on 273 previous data (14), we can therefore hypothesise that despite the extremely low levels of PrP-res 274 identified in both brain and spleen of these mice following NaPTA precipitation the titre of 275 infectivity in each tissue is similar, at approximately10 7 -10 9 IU/g. Thus the spleen tissue 276 maintains the discrepancy observed in the brain tissue of these unique disease models with high 277 infectivity levels observed despite the presence of low levels or an absence of PrP-res. Full 278 titration studies are currently planned to accurately establish the infectious titre in the spleen 279 tissues of the 101LL/GSS and 101LL/263K mice. However, the initial data from this disease 280 model prove that TSE agents can have the potential to replicate to high infectivity levels in 281 peripheral tissues when the combination of host species, PrP genotype and TSE agent provides 282 the correct conditions for replication of the infectious agent.
283
Previous studies of these disease models have shown the presence of little or no PrP-res in brain 284 tissue, despite relatively high levels of infectivity (14, 16, 17) . Further investigation here has now 285 demonstrated the presence of low levels of PrP-res in these tissues following concentration of 286 approximately 10mg of tissue homogenate by NaPTA precipitation. Interestingly, the levels of 287 PrP-res detected in brain and spleen of each mouse were similar, and experiments to determine 288 whether this is the truly infectious subpopulation of PrP Sc are on-going in our laboratory.
289
However, despite identifying similar levels of PrP-res in spleens of 101LL/GSS and 79A ( Figure   290 3), estimated levels of infectivity based on incubation times were significantly higher in 291 101LL/GSS spleen homogenates. Moreover, 101LL/263K(d) was able to transmit disease from 292 both the brain and spleen tissue despite the absence of PrP-res in the residual inocula of both 293 tissues even with the inclusion of NaPTA precipitation as a concentration step to increase the 294 sensitivity levels. Together these data support the continued lack of correlation between PrP-res 295 levels and infectivity in these mouse models of disease.
296
Given both 101LL/GSS and 101LL/263K had similar incubation periods to disease from both 297 brain and spleen tissue, it can be presumed that this unexpected result was not solely due to the 298 strain of TSE agent or compatibility at codon 101/102. Indeed, the hamster 263K scrapie strain is 299 propagated in animals with proline at PrP codon 102 (equivalent to codon 101 in mice), and does 300 not produce the same disease phenotype when passaged in hamsters. Therefore the disease 301 phenotype in 101LL mice is not an intrinsic characteristic of the strain but rather due to the 302 specific combination of host species, PrP genotype and strain of agent that allows this disease 303 phenotype of high infectivity levels but extremely low levels of PrP-res to manifest. It is possible 304 that this phenotype is uniquely due to the 101L mutation in the recipient mice altering disease 305 pathogenesis or selecting a different isolate from the heterogeneous population of the infectious 306 agent. Further analyses of other TSE strains (e.g. ME7, 79A, 301V) in these mice (which show 307 similar PrP-res levels to wild type mice; (22)) are planned to address this issue.
308
Several recent studies have identified the presence of quasi-species present within individual 309 cases of TSE disease in humans (23, 24), animals (25) and in cell-culture models (26). Indeed it 310 has been hypothesised that sub-variants of disease-associated PrP replicate preferentially in a 311 specific tissue type with dependence on tissue-specific host factors (25, 27) . The biochemical 312 and immunohistochemical analysis of the recipient mice from the 101LL/GSS sub-passage 313 demonstrated that PrP-res deposition was lower in the brain tissue of mice that received the 314 spleen homogenate inocula compared to those that received the brain homogenate inocula 315 ( Figure 6 ) whilst in contrast the vacuolation score in mice was greater in those that received the 316 spleen homogenate than the brain homogenate ( Figure 4) . These results indicate that a potentially 317 heterogeneous population of PrP-res was present. It is hypothesised that tissue-specific 318 conditions supported replication of different sub-variants that upon sub-passage showed different 319 replication efficiencies. If heterogeneous populations of PrP-res exist with variants that have 320 different replication capabilities, a variant present in peripheral tissues may have a higher level 321 of infectivity than the corresponding brain-derived variant. Therefore assessment of the 322 peripheral infectivity levels from novel and emerging isolates is urgently required to ensure an 323 accurate titre is established to maintain food safety.
324
Together these results indicate that a form of the infectious agent may be present in this disease 325 model that remains undetectable by current standard analysis. Given the increasing costs of sheep BSE and indicated that quantitative laboratory tests to detect disease-associated PrP could 336 not be used to accurately predict infectious titres (28).While TSEs remain in the environment, the 337 emergence of novel isolates, or the possibility that a known isolate could infect a different host 338 species remains. Our data show that a combination of host species, PrP genotype and TSE isolate 339 has the potential to occur that could produce a novel disease phenotype with high levels of TSE 340 infectivity in the absence of PrP-res. Therefore if infectivity levels in the peripheral tissues of 341 disease cases with low levels of PrP-res are higher than originally hypothesised from previous 342 research into classical isolates and current biochemical tests, the emergence of a novel isolate 343 could pose a major risk to food safety if tissues were able to enter the food chain. Together with 344 the discrepancy between PrP-res and TSE infectivity levels presented here, the estimation of titre 345 should not rely on the detection of PrP-res as the sole indicator of TSE disease. homogenate was loaded on each blot to provide PrP C band as internal control. Blots probed with 449 mAb 8H4 and exposed for 5 minutes. transmission of brain and spleen tissue from wild-type mice were statistically different, with 454 longer incubation periods produced from inoculation with spleen tissue (blue bars). Statistics 455 calculated with student's two-tailed t-test with p-values of 2.88x10 -5 , 3.66x10 -6 , and 1.08x10 -8 456 for 10 -2 , 10 -3 and 10 -4 groups respectively for wild-type/79A transmission. One 101LL/GSS(a) 457 dilution, 10 -3 produced a significant difference (p-value 8.3x10 -5 ) and one 101LL/GSS(b) 458 dilution, 10 -2 produced a significant difference (p-value 5.6x10 -4 ). NaPTA precipitation. In contrast PrP-res was present in wild-type/79A brain and spleen 462 residual homogenates. Residual homogenates were PK digested, NaPTA precipitated. Samples 463 were loaded at a wet weight tissue equivalent of 10mg, proteins separated by SDS-PAGE.
464
Immunoblots probed with mAb 8H4 and exposed for 10 minutes. higher vacuolation level was observed after inoculation of the spleen tissue compared to the 470 brain tissue. In comparison, the lesion profiles from inoculation of brain and spleen tissue from 471 wild-type/79A mice (E) followed the same pattern with inoculation of the brain tissue producing 472 a slightly higher vacuolation level than the spleen tissue. 
